Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX--These data have been accepted for oral presentation at the American Academy of Pain Medicine ...
Tamil Nadu's rising oral cancer cases call for urgent awareness, early detection, and effective tobacco cessation strategies ...
RIPPLE(TM) (Remote Induction of Pulsed Pressure Lateral to Energy) is a proprietary ultrasound-mediated delivery technology. -- RIPPLE(TM) has been developed to enable efficient, redosable, targeted, ...
RIPPLE™ (Remote Induction of Pulsed Pressure Lateral to Energy) is a proprietary ultrasound-mediated delivery ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
When dentist Dr Loo Yie Jin was told that his pancreatic cancer had spread to his liver, the news was devastating. He had ...
Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...
Mr Abraham Koomson, Secretary-General of the Ghana Federation of Labour (GFL), has applauded President John Dramani Mahama ...
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C ...
The MarketWatch News Department was not involved in the creation of this content.-- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was ...
Zurletrectinib has also been included in the “SPARK Program” by the CDE, a pilot initiative to encourage the development of pediatric anti-tumor drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results